Increased expression of three-repeat isoforms of tau contributes to tau pathology in a rat model of chronic type 2 diabetes

Experimental Neurology

Volumn 228, Issue 2, 2011, Pages 232-241

  Jung, Hyun Jung ^a   Park, Seok Soon ^a   Mok, Ji Oh ^a   Lee, Tae Kyeong ^a   Park, Choon Sik ^a   Park, Sun Ah ^a  

^a Soonchunhyang University   (South Korea)

Author keywords

Alzheimer's disease; Isoform; Splicing; Tau; Type 2 diabetes

Indexed keywords

ISOPROTEIN; TAU PROTEIN;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUCLEOTIDE SEQUENCE; OTSUKA LONG EVANS TOKUSHIMA FATTY RAT; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; TAUOPATHY;

ALZHEIMER DISEASE; ANIMALS; CHRONIC DISEASE; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; PROTEIN ISOFORMS; RATS; RATS, INBRED OLETF; REPETITIVE SEQUENCES, AMINO ACID; TAU PROTEINS; TAUOPATHIES;

EID: 79952703206     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2011.01.012     Document Type: Article

References (57)

1. Alonso A., Zaidi T., Novak M., Grundke-Iqbal I., Iqbal K. Hyperphosphorylation induces self-assembly of tau into tangles of paired helical filaments/straight filaments. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:6923-6928.
2. Alonso A.D., Di Clerico J., Li B., Corbo C.P., Alaniz M.E., Grundke-Iqbal I., Iqbal K. Phosphorylation of tau at Thr212, Thr231, and Ser262 combined causes neurodegeneration. J. Biol. Chem. 2010, 285:30851-30860.
3. Andorfer C., Kress Y., Espinoza M., de Silva R., Tucker K.L., Barde Y.A., Duff K., Davies P. Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms. J. Neurochem. 2003, 86:582-590.
4. Andreadis A. Tau gene alternative splicing: expression patterns, regulation and modulation of function in normal brain and neurodegenerative diseases. Biochim. Biophys. Acta. 2005, 1739:91-103.
5. Arvanitakis Z., Wilson R.S., Bienias J.L., Evans D.A., Bennett D.A. Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch. Neurol. 2004, 61:661-666.
6. Arvanitakis Z., Schneider J.A., Wilson R.S., Li Y., Arnold S.E., Wang Z., Bennett D.A. Diabetes is related to cerebral infarction but not to AD pathology in older persons. Neurology. 2006, 67:1960-1965.
7. Beeri M.S., Schmeidler J., Silverman J.M., Gandy S., Wysocki M., Hannigan C.M., Purohit D.P., Lesser G., Grossman H.T., Haroutunian V. Insulin in combination with other diabetes medication is associated with less Alzheimer neuropathology. Neurology. 2008, 71:750-757.
8. Busciglio J., Lorenzo A., Yeh J., Yankner B.A. beta-amyloid fibrils induce tau phosphorylation and loss of microtubule binding. Neuron. 1995, 14:879-888.
9. Butner K.A., Kirschner M.W. Tau protein binds to microtubules through a flexible array of distributed weak sites. J. Cell. Biol. 1991, 115:717-730.
10. Calon F., Lim G.P., Yang F., Morihara T., Teter B., Ubeda O., Rostaing P., Triller A., Salem N., Ashe K.H., Frautschy S.A., Cole G.M. Docosahexaenoic acid protects from dendritic pathology in an Alzheimer's disease mouse model. Neuron. 2004, 43:633-645.
11. Chen K.L., Yuan R.Y., Hu C.J., Hsu C.Y. Amyloid-β peptide alteration of tau exon-10 splicing via the GSK3β-SC35 pathway. Neurobiol. Dis. 2010, 40:378-385.
12. Connell J.W., Rodriguez-Martin T., Gibb G.M., Kahn N.M., Grierson A.J., Hanger D.P., Revesz T., Lantos P.L., Anderton B.H., Gallo J.M. Quantitative analysis of tau isoform transcripts in sporadic tauopathies. Brain. Res. Mol. Brain. Res. 2005, 137:104-109.
13. Cowan C.M., Bossing T., Page A., Shepherd D., Mudher A. Soluble hyper-phosphorylated tau causes microtubule breakdown and functionally compromises normal tau in vivo. Acta. Neuropathol. 2010, 120:593-604.
14. Craft S., Peskind E., Schwartz M.W., Schellenberg G.D., Raskind M., Porte D. Cerebrospinal fluid and plasma insulin levels in Alzheimer's disease: relationship to severity of dementia and apolipoprotein E genotype. Neurology. 1998, 50:164-168.
15. de Calignon A., Fox L.M., Pitstick R., Carlson G.A., Bacskai B.J., Spires-Jones T.L., Hyman B.T. Caspase activation precedes and leads to tangles. Nature. 2010, 464:1201-1204.
16. Deng Y., Li B., Liu Y., Iqbal K., Grundke-Iqbal I., Gong C.X. Dysregulation of insulin signaling, glucose transporters, O-GlcNAcylation, and phosphorylation of tau and neurofilaments in the brain: implication for Alzheimer's disease. Am. J. Pathol. 2009, 175:2089-2098.
17. Espinoza M., de Silva R., Dickson D.W., Davies P. Differential incorporation of tau isoforms in Alzheimer's disease. J. Alzheimers. Dis. 2008, 14:1-16.
18. Gärtner U., Janke C., Holzer M., Vanmechelen E., Arendt T. Postmortem changes in the phosphorylation state of tau-protein in the rat brain. Neurobiol. Aging. 1998, 19:535-543.
19. Gasparini L., Netzer W.J., Greengard P., Xu H. Does insulin dysfunction play a role in Alzheimer's disease?. Trends. Pharmacol. Sci. 2002, 23:288-293.
20. Geschwind D.H. Tau phosphorylation, tangles, and neurodegeneration: the chicken or the egg?. Neuron 2003, 40:457-460.
21. Glatz D.C., Rujescu D., Tang Y., Berendt F.J., Hartmann A.M., Faltraco F., Rosenberg C., Hulette C., Jellinger K., Hampel H., Riederer P., Möller H.J., Andreadis A., Henkel K., Stamm S. The alternative splicing of tau exon 10 and its regulatory proteins CLK2 and TRA2-BETA1 changes in sporadic Alzheimer's disease. J. Neurochem. 2006, 96:635-644.
22. Goode B.L., Chau M., Denis P.E., Feinstein S.C. Structural and functional differences between 3-repeat and 4-repeat tau isoforms. Implications for normal tau function and the onset of neurodegenetative disease. J. Biol. Chem. 2000, 275:38182-38189.
23. Grodstein F., Chen J., Wilson R.S., Manson J.E., Study Nurses' Health Type 2 diabetes and cognitive function in community-dwelling elderly women. Diabetes. Care. 2001, 24:1060-1065.
24. Hall G.F., Chu B., Lee G., Yao J. Human tau filaments induce microtubule and synapse loss in an in vivo model of neurofibrillary degenerative disease. J. Cell. Sci. 2000, 113:1373-1387.
25. Hanes J., Zilka N., Bartkova M., Caletkova M., Dobrota D., Novak M. Rat tau proteome consists of six tau isoforms: implication for animal models of human tauopathies. J. Neurochem. 2009, 108:1167-1176.
26. Heitner J., Dickson D. Diabetics do not have increased Alzheimer-type pathology compared with age-matched control subjects. A retrospective postmortem immunocytochemical and histofluorescent study. Neurology. 1997, 49:1306-1311.
27. Helkala E.L., Niskanen L., Viinamaki H., Partanen J., Uusitupa M. Short-term and long-term memory in elderly patients with NIDDM. Diabetes. Care. 1995, 18:681-685.
28. Ho L., Qin W., Pompl P.N., Xiang Z., Wang J., Zhao Z., Peng Y., Cambareri G., Rocher A., Mobbs C.V., Hof P.R., Pasinetti G.M. Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease. FASEB. J. 2004, 18:902-904.
29. Hoyer S. Brain glucose and energy metabolism abnormalities in sporadic Alzheimer disease. Causes and consequences: an update. Exp. Gerontol. 2000, 35:1363-1372.
30. Hoyer S. The aging brain. Changes in the neuronal insulin/insulin receptor signal transduction cascade trigger late-onset sporadic Alzheimer disease (SAD). A mini-review. J. Neural. Transm. 2002, 109:991-1002.
31. Ingelsson M., Ramasamy K., Cantuti-Castelvetri I., Skoglund L., Matsui T., Orne J., Kowa H., Raju S., Vanderburg C.R., Augustinack J.C., de Silva R., Lees A.J., Lannfelt L., Growdon J.H., Frosch M.P., Standaert D.G., Irizarry M.C., Hyman B.T. No alteration in tau exon 10 alternative splicing in tangle-bearing neurons of the Alzheimer's disease brain. Acta. Neuropathol. 2006, 112:439-449.
32. Kahn S.E. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes. Diabetologia. 2003, 46:3-19.
33. Kawano K., Hirashima T., Mori S., Saitoh Y., Kurosumi M., Natori T. Spontaneous long-term hyperglycemic rat with diabetic complications. Otsuka Long-Evans Tokushima Fatty (OLETF) strain. Diabetes. 1992, 41:1422-1428.
34. Ke Y.D., Delerue F., Gladbach A., Götz J., Ittner L.M. Experimental diabetes mellitus exacerbates tau pathology in a transgenic mouse model of Alzheimer's disease. PLoS. One. 2009, 4:e7917.
35. Kim B., Backus C., Oh S., Hayes J.M., Feldman E.L. Increased tau phosphorylation and cleavage in mouse models of type 1 and type 2 diabetes. Endocrinology. 2009, 150:5294-5301.
36. Kosik K.S., Orecchio L.D., Bakalis S., Neve R.L. Developmentally regulated expression of specific tau sequences. Neuron. 1989, 2:1389-1397.
37. Leibson C.L., Rocca W.A., Hanson V.A., Cha R., Kokmen E., O'Brien P.C., Palumbo P.J. Risk of dementia among persons with diabetes mellitus: a population-based cohort study. Am. J. Epidemiol. 1997, 145:301-308.
38. Li Z.G., Zhang W., Sima A.A. Alzheimer-like changes in rat models of spontaneous diabetes. Diabetes. 2007, 56:1817-1824.
39. Liu F., Grundke-Iqbal I., Iqbal K., Gong C.X. Contributions of protein phosphatases PP1, PP2A, PP2B, and PP5 to the regulation of tau phosphorylation. Eur. J. Neurosci. 2005, 22:1942-1950.
40. Liu F., Gong C.X. Tau exon 10 alternative splicing and tauopathies. Mol. Neurodegener. 2008, 3:8.
41. Liu F., Shi J., Tanimukai H., Gu J., Gu J., Grundke-Iqbal I., Iqbal K., Gong C.X. Reduced O-GlcNAcylation links lower brain glucose metabolism and tau pathology in Alzheimer's disease. Brain. 2009, 132:1820-1832.
42. Ott A., Stolk R.P., van Harskamp F., Pols H.A., Hofman A., Breteler M.M. Diabetes mellitus and the risk of dementia: the Rotterdam Study. Neurology. 1999, 53:1937-1942.
43. Panda D., Samuel J.C., Massie M., Feinstein S.C., Wilson L. Differential regulation of microtubule dynamics by three- and four-repeat tau: implications for the onset of neurodegenerative disease. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:9548-9553.
44. Peila R., Rodriguez B.L., Launer L.J. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: the Honolulu-Asia Aging Study. Diabetes 2002, 51:1256-1262. Honolulu-Asia Aging Study.
45. Rivera E.J., Goldin A., Fulmer N., Tavares R., Wands J.R., de la Monte S.M. Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer's disease: link to brain reductions in acetylcholine. J. Alzheimers. Dis. 2005, 8:247-268.
46. Schubert M., Brazil D.P., Burks D.J., Kushner J.A., Ye J., Flint C.L., Farhang-Fallah J., Dikkes P., Warot X.M., Rio C., Corfas G., White M.F. Insulin receptor substrate-2 deficiency impairs brain growth and promotes tau phosphorylation. J. Neurosci. 2003, 23:7084-7092.
47. Terry R.D., Masliah E., Salmon D.P., Butters N., DeTeresa R., Hill R., Hansen L.A., Katzman R. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann. Neurol. 1991, 30:572-580.
48. Thies E., Mandelkow E.M. Missorting of tau in neurons causes degeneration of synapses that can be rescued by the kinase MARK2/Par-1. J. Neurosci. 2007, 27:2896-2907.
49. Tun P.A., Nathan D.M., Perlmuter L.C. Cognitive and affective disorders in elderly diabetics. Clin. Geriatr. Med. 1990, 6:731-746.
50. Utton M.A., Gibb G.M., Burdett I.D., Anderton B.H., Vandecandelaere A. Functional differences of tau isoforms containing 3 or 4 C-terminal repeat regions and the influence of oxidative stress. J. Biol. Chem. 2001, 276:34288-34297.
51. Wang Y., Wang J., Gao L., Lafyatis R., Stamm S., Andreadis A. Tau exons 2 and 10, which are misregulated in neurodegenerative diseases, are partly regulated by silencers which bind a SRp30c.SRp55 complex that either recruits or antagonizes htra2beta1. J. Biol. Chem. 2005, 280:14230-14239.
52. Watson G.S., Craft S. The role of insulin resistance in the pathogenesis of Alzheimer's disease: implications for treatment. CNS. Drugs. 2003, 17:27-45.
53. Watson G.S., Peskind E.R., Asthana S., Purganan K., Wait C., Chapman D., Schwartz M.W., Plymate S., Craft S. Insulin increases CSF Abeta42 levels in normal older adults. Neurology. 2003, 60:1899-1903.
54. White M.F. IRS proteins and the common path to diabetes. Am. J. Physiol. Endocrinol. Metab. 2002, 283:E413-E422.
55. Woods Y.L., Cohen P., Becker W., Jakes R., Goedert M., Wang X., Proud C.G. The kinase DYRK phosphorylates protein-synthesis initiation factor eIF2Bepsilon at Ser539 and the microtubule-associated protein tau at Thr212: potential role for DYRK as a glycogen synthase kinase 3-priming kinase. Biochem. J. 2001, 355:609-615.
56. Xu W.L., Qiu C.X., Wahlin A., Winblad B., Fratiglioni L. Diabetes mellitus and risk of dementia in the Kungsholmen project: a 6-year follow-up study. Neurology. 2004, 63:1181-1186.
57. Yoon S.Y., Park J.S., Choi J.E., Choi J.M., Lee W.J., Kim S.W., Kim D.H. Rosiglitazone reduces tau phosphorylation via JNK inhibition in the hippocampus of rats with type 2 diabetes and tau transfected SH-SY5Y cells. Neurobiol. Dis. 2010, 40:449-455.